Everforth Inc quarterly report, Q2 FY2003

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2003, for On Assignment, Inc. (Note: The input metadata referenced "Everforth Inc," but the filing text explicitly identifies the registrant as On Assignment, Inc.). The company is a leading provider of skilled temporary professionals to clients in the science and healthcare industries, operating through two segments: Lab Support and Healthcare Staffing.

Key Financial Metrics

Metric Three Months Ended June 30, 2003 Six Months Ended June 30, 2003
Revenues $54,180,000 $112,004,000
Gross Profit $15,212,000 (28.1% margin) $30,691,000 (27.4% margin)
Operating Income (Loss) $(79,464,000) $(80,327,000)
Net Income (Loss) $(79,564,000) $(80,017,000)
Diluted EPS $(3.15) $(3.12)
Cash and Cash Equivalents $31,649,000 (as of June 30, 2003) N/A
Working Capital $53,146,000 N/A
Total Debt $0 (No long-term debt reported) N/A

Material Changes vs. Prior Period

  • Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $79,897,000 in the second quarter of 2003. This charge relates to the Healthcare Staffing segment and was driven by lower market capitalization, personnel reductions, and reduced projected operating results.
  • Revenue Decline: Revenues for the three months ended June 30, 2003, decreased 19.9% to $54.2 million compared to $67.6 million in the prior year period. Excluding the impact of the Health Personnel Options Corporation (HPO) acquisition, organic revenue declined 23.3%.
  • Segment Performance:
    • Lab Support: Revenues decreased 14.9% due to an 18.0% drop in the average number of temporary professionals on assignment and a 32.7% drop in permanent placement fees.
    • Healthcare Staffing: Revenues decreased 23.4% year-over-year. Excluding HPO, revenue dropped 43.6% due to a 36.4% decrease in temporary professionals on assignment.
  • Cost Structure: Cost of services as a percentage of revenue increased to 71.9% (from 70.2% in 2002). Selling, general, and administrative (SG&A) expenses increased to 27.3% of revenue (from 20.6% in 2002), partly due to $349,000 in severance and office closure costs.

Guidance, Outlook, and Risks

  • Management Commentary: Management attributes the decline to a slowdown in research and development spending, general economic conditions, and increased competition, particularly in the nurse travel business. The company is implementing cost rationalization strategies, including office closures and staff reductions.
  • Seasonality: The company notes that demand typically declines in the second quarter due to client vacation periods and student availability, which may impact growth.
  • Capital Allocation: The company repurchased 1,138,500 shares of common stock for $4,552,000 during the six-month period. A Stockholders Rights Plan (poison pill) was adopted in June 2003 to deter unsolicited takeovers.
  • Risks and Contingencies:
    • Goodwill: Significant remaining goodwill ($43,997,000) poses a risk of future write-downs if market conditions or operating results deteriorate further.
    • Competition: Intensifying price competition in the nurse travel market could reduce gross profit margins.
    • Workers' Compensation: The company is partially self-insured; changes in historical experience or industry trends could materially affect liabilities.

Investor Verification Checklist

  • Goodwill Valuation: Verify the assumptions used in the discounted cash flow analysis for the remaining $44 million goodwill balance to assess the risk of future impairments.
  • Organic Revenue Trends: Confirm the sustainability of the revenue decline in the Lab Support segment, specifically regarding the biotechnology sector slowdown.
  • Cost Rationalization Impact: Monitor whether the $762,000 in restructuring costs and office closures yield the expected long-term efficiency improvements.
  • Liquidity Position: Review the company's ability to fund operations without a formal borrowing facility, relying on cash reserves and internally generated cash flow.
  • Stock Repurchase Program: Assess the remaining authorization ($278,500 shares) and the strategic rationale for buybacks amidst significant operating losses.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.